INSERM U955-IMRB, Team Ghaleh, UPEC, Ecole Nationale Vétérinaire d'Alfort, Faculté de Santé, 8 rue du général Sarrail, 94000, Créteil, France.
CHIV, Villeneuve-Saint-Georges, France.
Basic Res Cardiol. 2024 Jun;119(3):481-503. doi: 10.1007/s00395-024-01043-3. Epub 2024 Mar 22.
Hypercholesterolemia is a major risk factor for coronary artery diseases and cardiac ischemic events. Cholesterol per se could also have negative effects on the myocardium, independently from hypercholesterolemia. Previously, we reported that myocardial ischemia-reperfusion induces a deleterious build-up of mitochondrial cholesterol and oxysterols, which is potentiated by hypercholesterolemia and prevented by translocator protein (TSPO) ligands. Here, we studied the mechanism by which sterols accumulate in cardiac mitochondria and promote mitochondrial dysfunction. We performed myocardial ischemia-reperfusion in rats to evaluate mitochondrial function, TSPO, and steroidogenic acute regulatory protein (STAR) levels and the related mitochondrial concentrations of sterols. Rats were treated with the cholesterol synthesis inhibitor pravastatin or the TSPO ligand 4'-chlorodiazepam. We used Tspo deleted rats, which were phenotypically characterized. Inhibition of cholesterol synthesis reduced mitochondrial sterol accumulation and protected mitochondria during myocardial ischemia-reperfusion. We found that cardiac mitochondrial sterol accumulation is the consequence of enhanced influx of cholesterol and not of the inhibition of its mitochondrial metabolism during ischemia-reperfusion. Mitochondrial cholesterol accumulation at reperfusion was related to an increase in mitochondrial STAR but not to changes in TSPO levels. 4'-Chlorodiazepam inhibited this mechanism and prevented mitochondrial sterol accumulation and mitochondrial ischemia-reperfusion injury, underlying the close cooperation between STAR and TSPO. Conversely, Tspo deletion, which did not alter cardiac phenotype, abolished the effects of 4'-chlorodiazepam. This study reveals a novel mitochondrial interaction between TSPO and STAR to promote cholesterol and deleterious sterol mitochondrial accumulation during myocardial ischemia-reperfusion. This interaction regulates mitochondrial homeostasis and plays a key role during mitochondrial injury.
高胆固醇血症是冠状动脉疾病和心脏缺血事件的一个主要危险因素。胆固醇本身也可能对心肌产生负面影响,而与高胆固醇血症无关。此前,我们报道心肌缺血再灌注会导致线粒体胆固醇和氧化固醇的有害积累,这种积累会被高胆固醇血症增强,并被转运蛋白(TSPO)配体所预防。在这里,我们研究了固醇在心肌线粒体中积累并促进线粒体功能障碍的机制。我们在大鼠中进行了心肌缺血再灌注实验,以评估线粒体功能、TSPO 和类固醇生成急性调节蛋白(STAR)水平以及相关的线粒体固醇浓度。大鼠接受胆固醇合成抑制剂普伐他汀或 TSPO 配体 4'-氯二氮䓬治疗。我们使用 Tspo 缺失大鼠进行表型特征分析。胆固醇合成的抑制减少了线粒体固醇的积累,并在心肌缺血再灌注期间保护了线粒体。我们发现,心脏线粒体固醇的积累是由于胆固醇流入增加的结果,而不是缺血再灌注期间其线粒体代谢的抑制。再灌注时线粒体胆固醇的积累与线粒体 STAR 的增加有关,但与 TSPO 水平的变化无关。4'-氯二氮䓬抑制了这一机制,并防止了线粒体固醇的积累和线粒体缺血再灌注损伤,这表明 STAR 和 TSPO 之间存在密切的合作。相反,Tspo 缺失(不改变心脏表型)消除了 4'-氯二氮䓬的作用。这项研究揭示了心肌缺血再灌注期间 TSPO 和 STAR 之间一种新的线粒体相互作用,以促进胆固醇和有害固醇的线粒体积累。这种相互作用调节线粒体的动态平衡,并在线粒体损伤中发挥关键作用。